Breast Cancer

Evaluates why women who are at high risk for developing breast cancer decide to take or not take medication that will reduce their breast cancer risk.
Participants must be English speaking women 35 years of age or greater who have been identified as high risk.
Exclusions include, but are not limited to: Previous breast cancer, Ductal Carcinoma in Situ, Lobular Carcinoma in Situ or previous history of Raloxifene or Tamoxifen use.

Radiation with or without Herceptin after surgery for women with Her 2 positive Ductal Carcinoma in situ.
Participants can have Ductal Carcinoma in situ and Lobular Carcinoma in situ, but not invasive. Lumpectomy surgery only. Participation must begin prior to the 120th day from surgery.
Exclusions include, but are not limited to: Contralateral breast cancer, multicentric disease, partial breast radiation, active cardiac disease, uncontrolled blood pressure, history of CHF, cardiomyopathy or a recent MI.

Chemotherapy with or without Herceptin after surgery for women with low Her2 who are at high risk for recurrence of their breast cancer.
Participants can have unilateral invasive adenocarcinoma stage pT1 – 3, N0 – 3b, M0 and have received either Sentinel lymph node disection or Complete lymph node disection.
Exclusions include, but are not limited to: Uncontrolled hypertension or active Hepatitis B or C.

Study evaluating the use of heart protecting medications (Lisinopril, Coreg CR or placebo) to reduce the risk of heart problems for women receiving Herceptin after their breast cancer surgery.
Participants must be scheduled to receive Herceptin with or without chemotherapy.
Exclusions include, but are not limited to:prior Anthrocycline or Herceptin therapy, current treatment with an ACE inhibitor, Beta Blocker or Diogoxin, known MI, heart failure, cardiac dysfunction, bronchial asthma, bronchiodemea or severe angioedema.

Chemotherapy and Herceptin,after surgery, with or without a new agent for women with Her2 positive breast cancer.
Participants must be between 3-7 weeks post op. Multifocal disease and synchronous bilateral disease are allowed.
Exclusions include, but are not limited to: History of prior breast cancer, inflammatory breast disease, prior chemotherapy, prior radiation therapy or angina requiring anti-anginal medications.

Evaluates the effects of whole breast radiation on the appearance of the breast for women who receive radiation following surgery.
Participants must be in the post-op period with whole breast radiation being planned.
Exclusions include, but are not limited to: prior radiation, concurrent chemotherapy, immediate reconstruction or brachytherapy.

Lakeland Regional Medical Center